Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 25.4 USD 3.04% Market Closed
Market Cap: 3.2B USD
Section:
 

Relative Value

The Relative Value of one APLS stock under the Base Case scenario is 56.49 USD. Compared to the current market price of 25.4 USD, Apellis Pharmaceuticals Inc is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APLS Relative Value
Base Case
56.49 USD
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
90
vs Industry
67
Median 3Y
9.1
Median 5Y
17.4
Industry
7.8
Forward
3.2
More Details
71.4
P/E
P/E
Price to Earnings
71.4
vs History
0
vs Industry
Median 3Y
-12.7
Median 5Y
-10.9
Industry
24.1
Forward
95.8
More Details
40.7
P/OCF
P/OCF
Price to OCF
40.7
vs History
4
vs Industry
Median 3Y
-11.9
Median 5Y
-11.9
Industry
21.8
More Details
83.8
P/FCFE
P/FCFE
Price to FCFE
83.8
vs History
0
vs Industry
Median 3Y
-11.7
Median 5Y
-11.7
Industry
23.8
More Details
8
P/B
P/B
Price to Book Value
8
vs History
84
vs Industry
6
Median 3Y
17.9
Median 5Y
17.9
Industry
3.3
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
92
vs Industry
56
Median 3Y
9.1
Median 5Y
16.3
Industry
8
Forward
3.1
More Details
3.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.4
vs History
80
vs Industry
58
Median 3Y
10.5
Median 5Y
12.6
Industry
10.3
More Details
37.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37.7
vs History
0
vs Industry
Median 3Y
-13.9
Median 5Y
-13.1
Industry
6.3
Forward
35.9
More Details
38.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
38.5
vs History
0
vs Industry
Median 3Y
-13.8
Median 5Y
-13
Industry
6.7
Forward
45.9
More Details
39.2
EV/OCF
EV/OCF
Enterprise Value to OCF
39.2
vs History
4
vs Industry
Median 3Y
-11.8
Median 5Y
-11.6
Industry
7.9
More Details
39.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
39.4
vs History
4
vs Industry
Median 3Y
-11.8
Median 5Y
-11.6
Industry
6.3
More Details
5.7
EV/IC
EV/IC
Enterprise Value to IC
5.7
vs History
92
vs Industry
25
Median 3Y
9.6
Median 5Y
23.6
Industry
5.5
More Details

Multiples Across Competitors

APLS Competitors Multiples
Apellis Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
3.2B USD 3.2 71.4 37.7 38.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
402.8B USD 6.8 171.5 16.6 23.5
US
Amgen Inc
NASDAQ:AMGN
178.3B USD 5 25.5 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.9B USD 10 31.8 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.1B USD 5.8 17.9 17.1 19.4
AU
CSL Ltd
ASX:CSL
85.2B AUD 3.6 18.9 12.8 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.7B USD 16.7 1 233.4 162.1 196.6
NL
argenx SE
XBRU:ARGX
44.6B EUR 14.6 34.2 59 60.6
P/E Multiple
Earnings Growth PEG
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average P/E: 180.4
71.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 233.4
N/A N/A
NL
argenx SE
XBRU:ARGX
34.2
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average EV/EBITDA: 40
37.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.1
N/A N/A
NL
argenx SE
XBRU:ARGX
59
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average EV/EBIT: 45.6
38.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.6
N/A N/A
NL
argenx SE
XBRU:ARGX
60.6
N/A N/A

See Also

Summary
APLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
APLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
APLS stock valuation using valuation multiples.
Wall Street Estimates
APLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
APLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.